Pacific Biosciences of California, Inc. (PACB)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$2.43-4.71%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · PACB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 160.0 | 154.0 | 200.5 | 128.3 | 130.5 | 78.9 | 90.9 | 78.6 | 93.5 | 90.7 | 92.8 | 60.6 | 28.2 | 26.0 | 33.9 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 93.5 | 90.7 | 92.8 | 60.6 | 28.2 | 26.0 | 33.9 |
| Cost of Revenues | 101.3 | 114.2 | 116.7 | 147.7 | 79.3 | 71.7 | 46.3 | 56.3 | 53.5 | 58.8 | 46.6 | 39.3 | 37.2 | 21.8 | 25.0 | 20.8 |
| Gross Profit | 57.9 | 45.8 | 37.3 | 52.8 | 49.0 | 58.9 | 32.6 | 34.6 | 25.1 | 34.7 | 44.2 | 53.5 | 23.4 | 6.4 | 0.9 | 13.0 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 129.7 | 141.5 | 175.0 | 169.8 | 160.9 | 124.1 | 72.8 | 75.5 | 63.5 | 59.1 | 47.8 | 45.2 | 38.0 | 38.7 | 47.7 | 46.7 |
| R&D Expenses | 88.4 | 97.3 | 134.9 | 187.2 | 193.0 | 112.9 | 64.2 | 59.6 | 62.6 | 65.3 | 67.6 | 60.4 | 48.2 | 45.2 | 47.6 | 76.1 |
| Operating Income | (133.0) | (553.9) | (474.3) | (334.5) | (307.2) | (210.4) | (104.4) | (100.5) | (101.0) | (89.8) | (71.2) | (29.1) | (62.9) | (77.5) | — | — |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 7.0 | 13.4 | 14.3 | 14.7 | 12.5 | 0.3 | 2.6 | 2.4 | 2.9 | 3.2 | 2.9 | 2.8 | 2.5 | — | — |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
| EBT, Incl. Unusual Items | (130.6) | (546.1) | (309.5) | (318.2) | (314.2) | (274.9) | 29.4 | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | 0.8 | 0.3 | 0.3 | (11.4) | 0.0 | (93.6) | — | — | — | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (131.4) | (546.4) | (309.9) | (306.7) | (314.2) | (181.2) | 29.4 | (84.1) | (102.6) | (92.2) | (74.4) | (31.7) | (66.2) | (79.3) | (94.5) | (109.4) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.42) | (1.82) | (1.13) | (1.21) | (1.40) | (0.89) | 0.18 | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.42) | (1.82) | (1.59) | (1.21) | (1.40) | (0.89) | 0.17 | — | — | — | — | — | — | — | — | — |
| Dividend per Share | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Basic Weighted Avg Shares | 310.7 | 300.0 | 274.5 | 253.6 | 224.6 | 204.1 | 165.2 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 310.7 | 300.0 | 288.4 | 253.6 | 224.6 | 204.1 | 175.0 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | (93.8) | (81.3) | (67.4) | (25.5) | (58.6) | (71.9) | — | — |
| EBIT | (133.0) | (553.9) | (474.3) | (334.5) | (307.2) | (210.4) | (104.4) | (100.5) | (101.0) | (89.8) | (71.2) | (29.1) | (62.9) | (77.5) | — | — |
| Effective Tax Rate | -0.6% | — | — | 3.6% | 0.0% | 34.1% | — | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.